It was reported that development of a high-grade glioma phenotype was associated with temozolomide-driven hypermutation and acquired alterations of the cell cycle regulators CDKN2A and CCND2, which have been shown to occur exclusively in post-radiation IDH—mutant gliomas [47,48]. Here, CDKN2A is linked to central nervous system cancer.